SIBO Found in 50% of CIPO Patients via Breath Test

A Breath Test for SIBO Found Hydrogen-Positive SIBO in 50% of CIPO Patients

In a 2025 study at Niigata University, Japanese gastroenterologists gave a 50-gram glucose breath test to 10 patients with chronic intestinal pseudo-obstruction (CIPO). They found hydrogen-positive SIBO in five of them. None of the 10 healthy controls had this result. The data suggest CIPO, a severe motility disorder, creates an environment where hydrogen-producing bacteria thrive in the small intestine. This finding links a specific gas profile to a specific clinical condition, illustrating the breath test’s diagnostic role.

The Science of Breath Testing for SIBO

SIBO breath tests measure hydrogen and methane gases produced when gut bacteria ferment a test sugar. Humans cannot produce these gases. Elevated hydrogen levels within 90-120 minutes of ingesting glucose or lactulose indicate bacterial overgrowth in the small intestine. Methane production is linked to archaea called methanogens. The North American Consensus sets diagnostic thresholds: a rise in hydrogen of 20 parts per million (ppm) from baseline or a methane level of 10 ppm or more at any point.

Hydrogen vs. Methane: A Critical Diagnostic Distinction

The Japanese CIPO study highlights the importance of interpreting hydrogen and methane separately. All five positive CIPO cases were hydrogen-positive. No patient met the criteria for intestinal methanogen overgrowth (IMO), where methane is dominant. This hydrogen-exclusive profile may be characteristic of motility disorders. In contrast, IMO is more commonly associated with constipation-predominant conditions. Recognizing this distinction directly influences treatment strategy, as methane-positive overgrowth often requires different antimicrobial approaches.

Test-Retest Study Reveals 31% Variation in Healthy Controls

Researchers from the Neurogastroenterology and Motility Unit in Mexico conducted a study to assess the reliability of SIBO breath tests. They performed two identical tests, one week apart, on a cohort of 50 healthy adults without gastrointestinal symptoms. Their results, published in Neurogastroenterology and Motil, found a 31% variation in test results between the first and second administration. A positive result on the first test did not reliably predict a positive on the second. This inherent variability is a significant limitation clinicians must account for when interpreting a single test.

Factors Influencing Breath Test Results

Several variables can affect breath gas levels, contributing to the observed variability. The preparation phase is critical. Patients must follow a strict 24-hour low-fiber diet and fast for 12 hours to establish a true baseline. Physical activity, smoking, and sleep during the test can alter gut motility and gas production. The gut’s microbial composition itself may shift day-to-day. Furthermore, the test substrate matters. Glucose is absorbed in the proximal small intestine, so it may miss overgrowth in more distal regions, a limitation noted by the Niigata University team.

How to Interpret a Positive or Negative Result

A positive breath test, particularly for hydrogen, should be interpreted in the context of the patient’s symptoms. It is not a standalone disease diagnosis but a sign of a probable microbial imbalance. A positive test with symptoms like bloating, diarrhea, and abdominal pain supports a SIBO diagnosis. A negative test, however, does not definitively rule out SIBO, especially if symptoms persist. The 2025 reliability study indicates a single negative test has a 20% chance of being positive on retest. Therefore, clinical judgment remains paramount.

Clinical Applications and Limitations of Current Protocols

The glucose breath test used in the CIPO study is a standard tool. Its value lies in its non-invasive nature and ability to provide a functional measurement of small intestinal fermentation. It can guide targeted antibiotic therapy, such as rifaximin for hydrogen-dominant SIBO. However, its limitations are real. The lactulose breath test, while better for detecting distal overgrowth, can produce false positives due to rapid transit. Neither test identifies the specific bacterial species present, only their metabolic output. The test-retest variability problem means it is not ideal for monitoring treatment efficacy in the short term.

Actionable Steps for Patients and Practitioners

For a patient preparing for a breath test, strict adherence to the prep diet is the most important action. During the test, consistent sampling times must be followed. For the practitioner, the test result is a piece of a larger puzzle. A hydrogen-positive result in a patient with diarrhea and a history of motility disorder, like CIPO, strongly supports a SIBO diagnosis and justifies treatment. A methane-positive result in a patient with severe constipation suggests IMO and may require a combination of rifaximin and neomycin. Symptom correlation is essential; treating a positive test in an asymptomatic individual is not recommended.

Dietary management often follows a positive diagnosis. A low FODMAP diet can reduce symptoms by limiting fermentable substrates for gut bacteria. For patients with methane-associated constipation, dietary approaches may differ, focusing more on motility support. The evidence suggests dietary strategies should be individualized.

Future Directions in Breath Testing and Microbial Analysis

Current research is moving beyond simple gas measurement. Scientists are investigating the role of hydrogen sulfide gas, which requires a separate sensor not included in standard tests. There is also interest in quantifying the proportion of gases, not just absolute levels, to better define overgrowth subtypes. Direct culture of small intestinal fluid, obtained via endoscopy, remains the gold standard but is invasive and not routine. Future diagnostic models may combine breath testing with microbiome sequencing of stool samples to create a more comprehensive picture of upper and lower gut dysbiosis.

Key Takeaways

• SIBO breath tests measure bacterial fermentation gases (hydrogen and methane) and have defined diagnostic thresholds, but inherent test-retest variability exists.
• Hydrogen-positive SIBO was strongly associated with chronic intestinal pseudo-obstruction in a Japanese cohort, while methane overgrowth was not, highlighting distinct gas phenotypes for different conditions.
• A single negative breath test does not definitively exclude SIBO due to the test’s variable reliability; clinical symptoms must guide decision-making.
• Strict patient preparation is critical for obtaining a valid breath test result, as diet, fasting, and activity can significantly alter gas readings.
• Breath test results should inform, not dictate, treatment. A hydrogen-positive result typically guides therapy differently than a methane-positive result.
• The test is best used as a diagnostic aid for symptomatic patients, not as a screening tool for asymptomatic individuals.

This article is for informational purposes only. Consult a qualified professional for personalised advice.

Sources:
https://pubmed.ncbi.nlm.nih.gov/41209870/
https://pubmed.ncbi.nlm.nih.gov/40420410/
https://pubmed.ncbi.nlm.nih.gov/40307658/